Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Project Updates and Milestones news
(page 42)
27 February 2026
Merck's KEYTRUDA and Padcev Cut Event-Free Survival Risk by 47% and Mortality by 35% in Cisplatin-Eligible Bladder Cancer Patients
KEYTRUDA plus Padcev improves survival and reduces recurrence in muscle-invasive bladder cancer, showing potential as a new standard for cisplatin-eligible patients.
27 February 2026
Lilly's Olumiant Gains CHMP Nod for Adolescent Alopecia Areata in EU
CHMP backs Olumiant for severe alopecia areata in adolescents, based on Phase 3 study showing 42% achieved 80% scalp hair coverage at 36 weeks. Awaiting European Commission decision.
27 February 2026
KazMunayGas 2025 Trading Update
Hydrocarbon reserves stable; oil and gas production up. Oil transport steady; refining and polypropylene output increased.
27 February 2026
Air Liquide and Holcim Partner to Decarbonize Belgian Cement Production
The agreement aims to capture 1.1 million tons of CO₂ annually at Holcim's Obourg plant, supporting EU's 2050 net zero target through advanced carbon capture and storage technology.
27 February 2026
BASF Advances "Winning Ways" Strategy Milestones
BASF boosts free cash flow, starts Zhanjiang plants, and cuts costs. 2025 EBITDA drops to €6.6B; 2026 outlook: €6.2-7.0B EBITDA, €1.5-2.3B free cash flow.
26 February 2026
GSK's Bepirovirsen Under Review in Japan for Chronic Hepatitis B Treatment
Japan reviews bepirovirsen for chronic hepatitis B. Phase III trials show higher functional cure rates and acceptable safety. SENKU designation granted for expedited review.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
26 February 2026
GSK's Linerixibat Gets Priority Review in China for PBC-Related Itch
Linerixibat shows significant improvement in cholestatic pruritus in PBC patients, based on GLISTEN phase III trial data. Regulatory reviews ongoing in US, EU, UK, and Canada.
26 February 2026
PureCycle Technologies Q4 2025 Results and Update
Record production, revenue growth, expansion in Thailand and Belgium, and leadership changes. Gen-2 design shows cost efficiency. Financials stable with ongoing projects and debt management.
26 February 2026
FDA Approves Boehringer Ingelheim's HERNEXEOS for HER2-Mutant NSCLC
HERNEXEOS gains FDA approval for HER2-mutant NSCLC, showing a 76% response rate in trials. Further confirmation required for continued approval.
26 February 2026
Johnson & Johnson Reports Positive Early Results for Pasritamig and Docetaxel in Prostate Cancer
Phase 1b study shows pasritamig and docetaxel combo is safe and effective in prostate cancer, with high PSA response rates, supporting Phase 3 trials.
26 February 2026
Lilly's Orforglipron Outperforms Semaglutide in Diabetes Trial
Orforglipron 36 mg reduced A1C by 2.2% and weight by 9.2%, surpassing semaglutide in a 52-week trial with 1,698 participants. Results published in The Lancet.
26 February 2026
Aramco Advances Gas Expansion with Jafurah and Tanajib Projects
Jafurah and Tanajib projects boost gas production, aiming for 80% capacity increase by 2030, supporting economic growth and energy diversification.
26 February 2026
Eni Reports Strong 2025 Financial and Strategic Progress
Strong Q4 results with 35% net income growth. Major projects launched, production up 7%. LNG expansion, biofuels growth, and strategic partnerships enhance resilience and shareholder returns.
26 February 2026
EEW Advances Flue Gas Cleaning Modernization in Helmstedt
EEW invests in flue gas cleaning to meet strict emissions, enhance environmental performance, and ensure long-term site viability during ongoing operations in Helmstedt.
26 February 2026
RWE Expands Italy's Wind and Solar Capacity to 235 MW
RWE doubles its renewable projects in Italy, adding 123 MW in 2026. New wind and solar projects will power 190,000 homes, with more developments planned.
25 February 2026
Statkraft–OX2 7‑year PPA to optimise two Finnish BESS (110 MW/220 MWh and 125 MW/250 MWh)
Two large-scale BESS (110 MW/220 MWh and 125 MW/250 MWh) will be optimised from 2028 under a seven-year PPA with a revenue-floor to support financing; co-located with wind sites.
25 February 2026
ViiV Healthcare: Lotivibart Shows 94% Viral Suppression in Long-Acting HIV Treatment
Lotivibart, combined with CAB LA, maintained viral suppression in 94% of participants. Study progresses to test twice-yearly dosing. Well-tolerated with fewer adverse events in IV group.
25 February 2026
Merck Animal Health's NUMELVI: FDA-Approved JAK Inhibitor for Canine Allergic Dermatitis
FDA approves NUMELVI for dogs 6+ months, a JAK inhibitor for allergic dermatitis, offering rapid itch relief and easy dosing. Available spring 2026.
25 February 2026
Merck Presents Phase 3 Trial Results for HIV-1 Treatment DOR/ISL at CROI 2026
DOR/ISL shows non-inferiority and similar safety to BIC/FTC/TAF in HIV-1 treatment-naïve adults and maintains suppression in those switching from other therapies.
25 February 2026
MOL and Janaf Agree on Adria Pipeline Capacity Tests
Long-term tests will assess Adria pipeline capacity. MOL seeks clarity on Russian oil shipments and criticizes Janaf's pricing. Two competitive routes are vital for regional supply security.
25 February 2026
Regulation Essential for OCCS Investment in Maritime Decarbonization
A DNV report highlights the need for clear regulations to advance OCCS technology, crucial for maritime decarbonization, with pilot projects showing technical feasibility and economic potential.
25 February 2026
Statkraft and OX2 Partner on Finland Battery Storage Optimization
Statkraft will optimize two large-scale battery systems in Finland, enhancing grid stability and renewable integration, starting in 2028 with a seven-year agreement.
25 February 2026
Worley Wins EPCM Contract for Danish Hydrogen Pipeline
Worley to provide EPCM services for Denmark's hydrogen pipeline, linking green hydrogen production with Germany, enhancing energy security and supporting the green transition.
24 February 2026
Solvay 2025 Q4 and Annual Financial Results
Strong cash flow of €350M in 2025 despite challenges. EBITDA at €881M, net profit at €306M. Sustainability goals on track. 2026 outlook: EBITDA €770-850M, Free Cash Flow €200M+.
24 February 2026
Technip Energies Secures Contract for Mozambique Coral Norte LNG Project
Coral Norte, Mozambique's second FLNG, progresses with proven design, enhancing efficiency and LNG capacity, following Coral Sul's success.
24 February 2026
Johnson & Johnson Seeks FDA Approval for IMAAVY® to Treat wAIHA
IMAAVY® targets wAIHA by blocking FcRn, reducing IgG. Phase 2/3 study shows improved hemoglobin and fatigue.
24 February 2026
Novo Nordisk's UBT251 Achieves 19.7% Weight Loss in Phase 2 China Trial
UBT251, a triple agonist, showed significant weight loss and improved health markers in a Chinese phase 2 trial, with a safe and well-tolerated profile.
24 February 2026
Rompetrol Rafinare Schedules Turnaround for Petromidia and Vega Refineries
Petromidia and Vega refineries will halt operations for a 20-day scheduled maintenance, focusing on inspections, equipment cleaning, and component replacements to ensure safety and efficiency.
23 February 2026
Johnson & Johnson's RYBREVANT® Approved for New Dosing Options in EGFR-Mutated Lung Cancer
European Commission approves subcutaneous RYBREVANT® for flexible dosing in advanced EGFR-mutated NSCLC, offering reduced clinic time and fewer reactions.
23 February 2026
LyondellBasell Updates 2030 Sustainability Goals
LYB revises 2030 goals: 32% emissions cut, 800,000 tons recycled polymers. Focus on circular, low-carbon growth, capital discipline, and sustainability.
← Previous
Next →
